Redox Regulation of m6A Methyltransferase METTL3 in Human β-cells Controls the Innate Immune Response in Type 1 Diabetes

Abstract

Type 1 Diabetes (T1D) is characterized by autoimmune-mediated destruction of insulin-producing {beta}-cells. Several observations have renewed interest in the innate immune system as an initiator of the disease process against {beta}-cells. Here, we show that N6-Methyladenosine (m6A) is an adaptive {beta}-cell safeguard mechanism that accelerates mRNA decay of the 2-5-oligoadenylate synthetase (OAS) genes to control the antiviral innate immune response at T1D onset. m6A writer methyltransferase 3 (METTL3) levels increase drastically in human and mouse {beta}-cells at T1D onset but rapidly decline with disease progression. Treatment of human islets and EndoC-{beta}H1 cells with pro-inflammatory cytokines interleukin-1 {beta} and interferon mimicked the METTL3 upregulation seen at T1D onset. Furthermore, m6A-sequencing revealed the m6A hypermethylation of several key innate immune mediators including OAS1, OAS2, and OAS3 in human islets and EndoC-{beta}H1 cells challenged with cytokines. METTL3 silencing in human pseudoislets or EndoC-{beta}H1 cells enhanced OAS levels by increasing its mRNA stability upon cytokine challenge. Consistently, in vivo gene therapy, to prolong Mettl3 overexpression specifically in {beta}-cells, delayed diabetes progression in the non-obese diabetic (NOD) mouse model of T1D by limiting the upregulation of Oas pointing to potential therapeutic relevance. Mechanistically, the accumulation of reactive oxygen species blocked METTL3 upregulation in response to cytokines, while physiological levels of nitric oxide promoted its expression in human islets. Furthermore, for the first time to our knowledge, we show that the cysteines in position C276 and C326 in the zinc finger domain of the METTL3 protein are sensitive to S-nitrosylation (SNO) and are significant for the METTL3 mediated regulation of OAS mRNA stability in human {beta}-cells in response to cytokines. Collectively, we report that m6A regulates human and mouse {beta}-cells to control the innate immune response during the onset of T1D and propose targeting METTL3 to prevent {beta}-cell death in T1D.